Natixis Eli Lilly & CO Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Eli Lilly & CO stock. As of the latest transaction made, Natixis holds 232,003 shares of LLY stock, worth $186 Million. This represents 1.17% of its overall portfolio holdings.

Number of Shares

232,003

Previous 158,143 46.7%

Holding current value

$186 Million

Previous $143 Million 43.55%

% of portfolio

1.17%

Previous 0.82%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$772.14 - $960.02 $57 Million - $70.9 Million	73,860 Added 46.7%	232,003 $206 Million
Q2 2024 Aug 13, 2024	SELL	$724.87 - $909.04 $45.9 Million - $57.6 Million	-63,373 Reduced 28.61%	158,143 $143 Million
Q1 2024 May 13, 2024	BUY	$592.2 - $792.28 $37.7 Million - $50.4 Million	63,654 Added 40.32%	221,516 $172 Million
Q4 2023 Feb 13, 2024	SELL	$525.19 - $619.13 $32.9 Million - $38.8 Million	-62,656 Reduced 28.41%	157,862 $92 Million
Q3 2023 Nov 14, 2023	SELL	$434.7 - $599.3 $56.3 Million - $77.6 Million	-129,555 Reduced 37.01%	220,518 $118 Million
Q2 2023 Aug 11, 2023	BUY	$350.74 - $468.98 $105 Million - $140 Million	298,949 Added 584.75%	350,073 $164 Million
Q1 2023 May 12, 2023	SELL	$310.63 - $364.82 $47.3 Million - $55.5 Million	-152,118 Reduced 74.85%	51,124 $17.6 Million
Q4 2022 Feb 24, 2023	BUY	$321.55 - $374.67 $10.5 Million - $12.2 Million	32,652 Added 19.14%	203,242 $74.4 Million
Q4 2022 Feb 13, 2023	SELL	$321.55 - $374.67 $54.7 Million - $63.8 Million	-170,217 Reduced 49.95%	170,590 $62.4 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $63.6 Million - $72.5 Million	214,678 Added 170.21%	340,807 $110 Million
Q2 2022 Aug 12, 2022	SELL	$278.73 - $327.27 $42.2 Million - $49.5 Million	-151,354 Reduced 54.55%	126,129 $40.9 Million
Q1 2022 May 13, 2022	BUY	$234.69 - $291.66 $34.6 Million - $43 Million	147,266 Added 113.09%	277,483 $79.5 Million
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $12 Million - $14.9 Million	53,289 Added 69.27%	130,217 $36 Million
Q3 2021 Nov 12, 2021	SELL	$221.6 - $272.71 $3.67 Million - $4.51 Million	-16,540 Reduced 17.7%	76,928 $17.8 Million
Q2 2021 Aug 13, 2021	BUY	$180.55 - $233.54 $12.7 Million - $16.5 Million	70,469 Added 306.4%	93,468 $21.5 Million
Q1 2021 May 14, 2021	SELL	$164.32 - $212.72 $56.4 Million - $73.1 Million	-343,527 Reduced 93.73%	22,999 $4.3 Million
Q4 2020 Feb 12, 2021	BUY	$130.46 - $172.63 $18 Million - $23.8 Million	137,953 Added 60.35%	366,526 $61.9 Million
Q3 2020 Nov 12, 2020	BUY	$146.22 - $169.13 $10.7 Million - $12.4 Million	73,096 Added 47.01%	228,573 $33.8 Million
Q2 2020 Aug 13, 2020	BUY	$136.42 - $164.18 $19 Million - $22.9 Million	139,396 Added 866.84%	155,477 $25.5 Million
Q1 2020 May 14, 2020	SELL	$119.05 - $147.35 $28 Million - $34.6 Million	-234,876 Reduced 93.59%	16,081 $2.23 Million
Q4 2019 Feb 14, 2020	BUY	$106.92 - $132.43 $18.4 Million - $22.8 Million	172,026 Added 217.94%	250,957 $33 Million
Q3 2019 Nov 13, 2019	BUY	$106.79 - $116.16 $8.43 Million - $9.17 Million	78,931 New	78,931 $8.83 Million
Q4 2018 Feb 14, 2019	SELL	$105.9 - $118.64 $38.1 Million - $42.7 Million	-360,151 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$85.86 - $107.31 $22.7 Million - $28.3 Million	263,825 Added 273.89%	360,151 $38.6 Million
Q2 2018 Aug 14, 2018	SELL	$75.7 - $86.88 $5.32 Million - $6.11 Million	-70,318 Reduced 42.2%	96,326 $8.22 Million
Q1 2018 May 15, 2018	BUY	$74.21 - $87.6 $4.26 Million - $5.02 Million	57,354 Added 52.48%	166,644 $12.9 Million
Q4 2017 Feb 14, 2018	SELL	$81.94 - $87.89 $22 Million - $23.6 Million	-268,822 Reduced 71.1%	109,290 $9.23 Million
Q3 2017 Nov 14, 2017	SELL	$77.07 - $85.54 $4.05 Million - $4.5 Million	-52,597 Reduced 12.21%	378,112 $32.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	430,709	430,709 $35.4 Million

Others Institutions Holding LLY

# of Institutions

4,007

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $760B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account